Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic Approach

Launched by GUSTAVE ROUSSY, CANCER CAMPUS, GRAND PARIS · Sep 23, 2020

Keywords

ClinConnect Summary

This clinical trial is looking to find new ways to understand cancer better by studying the bacteria and other tiny organisms that live in our bodies, known as the microbiome. Researchers are collecting samples from patients with cancer who are about to start their treatment. The goal is to see if there are certain patterns in the microbiome that can help predict how well a patient will respond to their cancer treatment.

To be eligible for this study, patients must have a cancer diagnosis and be starting treatment soon. They need to be able to give their consent and agree to participate in the study. However, pregnant or breastfeeding women, as well as those who cannot give their consent for any reason, cannot join. If you decide to participate, you can expect to provide some biological samples, and your information will be kept confidential. This study aims to improve how we treat cancer in the future by discovering important markers in the microbiome.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with cancer who will start treatment anticancer (see cohorts).
• • Patient information and signature of the consent form before any specific procedure for the study. The patient must be able and must be inclined to cooperate in the study procedures.
• • Patient affiliated to a social security scheme or beneficiary of a similar scheme.
• Exclusion Criteria:
• • Pregnant or lactating woman
• • Patient under guardianship or curatorship or deprived of liberty by a decision judicial or administrative or patient unable to give his consent.